Tissue Regenix Group
plc
('Tissue Regenix', the 'Group', or the
'Company')
Result of Annual General
Meeting
Tissue Regenix Group plc (AIM: TRX), the
regenerative medical devices company, announces that at the Annual
General Meeting ('AGM') held earlier today, all resolutions were
duly passed on a show of hands.
The results of the proxy votes
received in respect of the resolutions, given to the Chair prior to
the meeting, are set out below:
|
Resolution
|
|
In favour
|
%
|
Against
|
%
|
Withheld
|
|
1
|
Ordinary
|
30,257,029
|
99.99
|
610
|
0.01
|
12,274
|
|
2
|
Ordinary
|
30,249,468
|
99.98
|
7,296
|
0.02
|
13,149
|
|
3
|
Ordinary
|
30,254,468
|
99.99
|
2,296
|
0.01
|
13,149
|
|
4
|
Ordinary
|
30,254,468
|
99.99
|
2,296
|
0.01
|
13,149
|
|
5
|
Ordinary
|
30,254,968
|
99.99
|
1,796
|
0.01
|
13,149
|
|
6
|
Ordinary
|
30,254,468
|
99.99
|
2,296
|
0.01
|
13,149
|
|
7
|
Ordinary
|
30,254,468
|
99.99
|
2,296
|
0.01
|
13,149
|
|
8
|
Ordinary
|
30,255,203
|
99.99
|
1,561
|
0.01
|
13,149
|
|
9
|
Ordinary
|
30,255,203
|
99.99
|
2,436
|
0.01
|
12,274
|
|
10
|
Ordinary
|
30,253,968
|
99.96
|
11,671
|
0.04
|
4,274
|
|
11
|
Special
|
30,049,183
|
99.28
|
216,456
|
0.71
|
4,274
|
|
12
|
Special
|
30,236,441
|
99.93
|
21,198
|
0.07
|
12,274
|
Notes:
1. A "Vote
withheld" is not counted in the calculation of the percentage of
shares voted "In favour" or "Against".
2. As
at 23 April 2023, being the voting deadline date in respect of
the Annual General Meeting, the total number of Ordinary Shares of
0.1p each in issue and the total number of voting rights
was 70,574,468.
The full text of the resolutions
passed at the AGM may be found in the Notice of AGM published
on 19 March 2024.
For more
information:
|
Tissue Regenix
Group plc
|
www.tissueregenix.com
|
|
David Cocke, Chief Financial Officer
|
via Walbrook
PR
|
|
|
|
|
Cavendish
Capital Markets Limited (Nominated Adviser and
Broker)
|
|
|
Emily Watts/Geoff Nash/George Dollemore -
Corporate Finance
|
|
|
Nigel Birks/Harriet Ward - ECM
|
|
|
|
|
|
Walbrook PR (Financial PR and IR)
|
Tel: +44
(0)20 7933 8780
|
|
Alice Woodings/Charlotte Edgar
|
TissueRegenix@walbrookpr.com
|
|
|
| |
About Tissue Regenix
(www.tissueregenix.com)
Tissue Regenix is a leading medical device
company in regenerative medicine. The Company's patented
decellularisation technology (dCELL®) removes DNA and other
cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold not rejected by the patient's body that
can be used to repair diseased or damaged body structures. Current
applications address many crucial clinical needs in sports
medicine, foot and ankle injuries, and wound care.
In August 2017, Tissue
Regenix acquired CellRight Technologies®. This biotech company
specialises in regenerative medicine and is dedicated to developing
high-quality, innovative tissue scaffolds to enhance healing
opportunities in defects created by trauma and disease. CellRight's
human tissue products may be used in spine, trauma, general
orthopaedic, dental and ophthalmological surgical
procedures.
